tetano
Editor, Senior Moderator
PLoS One
. 2020 Sep 16;15(9):e0238614.
doi: 10.1371/journal.pone.0238614. eCollection 2020.
Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey
Shaikh Terkis Islam Pavel[SUP] 1 2 [/SUP], Hazel Yetiskin[SUP] 1 2 [/SUP], Gunsu Aydin[SUP] 1 2 [/SUP], Can Holyavkin[SUP] 3 [/SUP], Muhammet Ali Uygut[SUP] 2 [/SUP], Zehra Bestepe Dursun[SUP] 4 [/SUP], İlhami Celik[SUP] 4 [/SUP], Ceren Cevik[SUP] 3 [/SUP], Aykut Ozdarendeli[SUP] 1 2 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and associated with severe respiratory illness emerged in Wuhan, China, in late 2019. The virus has been able to spread promptly across all continents in the world. The current pandemic has posed a great threat to public health concern and safety. Currently, there are no specific treatments or licensed vaccines available for COVID-19. We isolated SARS-CoV-2 from the nasopharyngeal sample of a patient in Turkey with confirmed COVID-19. We determined that the Vero E6 and MA-104 cell lines are suitable for supporting SARS-CoV-2 that supports viral replication, development of cytopathic effect (CPE) and subsequent cell death. Phylogenetic analyses of the whole genome sequences showed that the hCoV-19/Turkey/ERAGEM-001/2020 strain clustered with the strains primarily from Australia, Canada, England, Iran and Kuwait and that the cases in the nearby clusters were reported to have travel history to Iran and to share the common unique nucleotide substitutions.
. 2020 Sep 16;15(9):e0238614.
doi: 10.1371/journal.pone.0238614. eCollection 2020.
Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey
Shaikh Terkis Islam Pavel[SUP] 1 2 [/SUP], Hazel Yetiskin[SUP] 1 2 [/SUP], Gunsu Aydin[SUP] 1 2 [/SUP], Can Holyavkin[SUP] 3 [/SUP], Muhammet Ali Uygut[SUP] 2 [/SUP], Zehra Bestepe Dursun[SUP] 4 [/SUP], İlhami Celik[SUP] 4 [/SUP], Ceren Cevik[SUP] 3 [/SUP], Aykut Ozdarendeli[SUP] 1 2 [/SUP]
Affiliations
- PMID: 32936826
- DOI: 10.1371/journal.pone.0238614
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and associated with severe respiratory illness emerged in Wuhan, China, in late 2019. The virus has been able to spread promptly across all continents in the world. The current pandemic has posed a great threat to public health concern and safety. Currently, there are no specific treatments or licensed vaccines available for COVID-19. We isolated SARS-CoV-2 from the nasopharyngeal sample of a patient in Turkey with confirmed COVID-19. We determined that the Vero E6 and MA-104 cell lines are suitable for supporting SARS-CoV-2 that supports viral replication, development of cytopathic effect (CPE) and subsequent cell death. Phylogenetic analyses of the whole genome sequences showed that the hCoV-19/Turkey/ERAGEM-001/2020 strain clustered with the strains primarily from Australia, Canada, England, Iran and Kuwait and that the cases in the nearby clusters were reported to have travel history to Iran and to share the common unique nucleotide substitutions.